Atypical phenylketonuria with normal phenylalanine hydroxylase and dihydropteridine reductase activity in vitro.
A child with phenylketonuria had normal phenylalanine hydroxylase activity in vitro. In addition, all known components of the phenylalanine hydroxylating system were within the normal range. Despite early treatment with a phenylalanine-restricted diet, the patient developed severe neurological symptoms. Although the primary molecular defect in this child is not known, there are indications that the defect lead to disturbances in phenylalanine metabolism and the biosynthesis of L-dopa and L-5-hydroxytryptophan. The administration of these two precursors of neurotransmitters brought a notable improvement in the patient's neurological symptoms.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D004093:Dihydropteridine Reductase / Q000032:analysis* / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007980:Levodopa / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism; D008297:Male; D009247:NADH, NADPH Oxidoreductases / Q000032:analysis*; D010651:Phenylalanine Hydroxylase / Q000032:analysis* / Q000378:metabolism; D010661:Phenylketonurias / Q000188:drug therapy / Q000201:enzymology*
D007980:Levodopa; D006916:5-Hydroxytryptophan; D010651:Phenylalanine Hydroxylase; D004093:Dihydropteridine Reductase; D009247:NADH, NADPH Oxidoreductases